Company Announcement - Oruka Therapeutics, Inc. has appointed Chris Martin to its Board of Directors, while Cameron Turtle has resigned effective December 11, 2025 [1][2] - The CEO, Lawrence Klein, expressed confidence in Martin's expertise to add value as the company advances its late-stage development programs, specifically ORKA-001 and ORKA-002 [2] Leadership Background - Chris Martin brings over 25 years of commercial experience, having most recently served as Chief Commercial Officer of Verona Pharma, which was acquired by Merck for approximately $10 billion in October 2025 [2] - At Verona, Martin was instrumental in building the commercial organization and launch strategy for Ohtuvayre (ensifentrine), which has seen rapid uptake for COPD treatment [2] Company Mission and Product Development - Oruka Therapeutics is focused on developing novel biologics aimed at treating chronic skin diseases, including plaque psoriasis, with a goal of achieving high rates of complete disease clearance [3] - The company aims to provide patients with the freedom from their conditions through infrequent dosing, potentially as little as once or twice a year [3] - Oruka is advancing a proprietary portfolio of antibodies engineered to target the core mechanisms of plaque psoriasis and other dermatologic and inflammatory diseases [3]
Oruka Therapeutics Announces New Board Member and Board Transition